
这个市场不值得进入,已经明显接近价格战区。 目前可识别的新品牌只有1个,且它的2个新上架里只有1个成功、1个失败,成功率50%看起来不差,但样本太小,不能说明市场宽松;更关键的是,整体新产品利润区间只有-1.60%到10.51%,绝大多数都卡在10%以下,说明这里不是“靠普通铺货就能赢”的市场。
These products have successfully captured market share and are profitable. Their design and features are suggested for your investment, based on market competition, saturation, and demand.
Green indicates better success rate, red indicates poorer success rate. If you are a new brand, focus on the left side; if you are an old brand, focus on the right side.
结论很明确:这个市场不值得进入。 你当前预算500,000 CNY只能覆盖单个ASIN的前期起步,但市场里基础款同质化严重、利润率偏低,已经接近价格战区;更关键的是,新品牌里只有ourmed的B0FZRR95CB跑通了,B0GJJQHTMW直接失败,说明不是“有钱就能赢”,而是必须靠明显差异化才能活下来。
Alternative solutions may pose a risk to your investment in certain markets.
这个市场不值得进入:利润率和成活率都暴露出明显的价格战风险,且新品牌表现是“1成活、1失败”的早期试探型市场,不是可复制的稳定机会。 对大品牌和小生意都不构成“高成功率”市场;大品牌可以靠资源硬打,但仍是高投入低确定性,小生意更不该进。
这个市场不适合进入,整体偏价格战且已有明显挤压。 目前可识别的样本里,只有16.67%产品盈利,且新产品盈利率虽然到50%,但样本只有2个,不能代表市场宽松;更关键的是,绝大多数已识别产品利润率都在10%以下,属于高风险价格战区。
All products profit ratio distribution, including all products. For products with insufficient sales or missing profit ratio data, they will be categorized into other rows. This distribution included products that cannot determine the release date.
This are the profit ratios of all new products. There are products without sufficient sales, no more than 100pcs in 3 months, or no profit ratio data, or just released. Those will be considered as 'other'
Most profitable products ranked by profit value. Only includes products with positive profitability and active sales, regardless of release date.
![]() | B0FZRR95CB | ourmed | 2025-11-05 | Yes | $16.64 | 100pcs | $1664.0 | 12.72% | $211.67 |
Most profitable new products ranked by profit value. Only includes newly released products with positive profitability and active sales.
![]() | B0FZRR95CB | ourmed | 2025-11-05 | Yes | $16.64 | 100pcs | $1664.0 | 12.72% | $211.67 |
这不是一个适合进入的市场:当前信号明确指向低利润、老品牌压制和新品牌高失败率。 仅有 2 个可识别品牌:新品牌 ourmed 只有 1 个盈利、1 个亏损,胜率 50%,但这只是样本极小的单品牌表现,不足以证明市场对新进入者友好;更关键的是,头部老品牌 All Health 在 4 个样本里 0 个盈利,说明这个品类已经被低价和同质化打穿,利润空间很薄。
What is the ratio of profitable products
What is the ratio of different brands owning all profitable new products
What is the ratio of different brands owning all nonprofitable new products
这个市场不值得进入,结论很明确:它已经接近价格战区,而且对新品牌并不友好。 目前可见的新品牌只有 ourmed,近两次新上架结果是一胜一负,成功率只有 50%,但真正能复制的“新品牌成功案例”只有 1 个,样本太小,不能当成可持续机会;同时老品牌 All Health 仍然占着基础款和大盘流量,说明这不是空白市场,而是被成熟产品卡住的存量竞争。
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
| Time/Profit% | x < -10.0% | -10.0% <= x < 0.0% | 0.0% <= x < 10.0% | 10.0% <= x < 20.0% | 20.0% <= x < 30.0% | 30.0% <= x < 40.0% | x >= 40.0% | other |
|---|---|---|---|---|---|---|---|---|
| 2022 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| 2026 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
| Time/Profit% | x < -10.0% | -10.0% <= x < 0.0% | 0.0% <= x < 10.0% | 10.0% <= x < 20.0% | 20.0% <= x < 30.0% | 30.0% <= x < 40.0% | x >= 40.0% | other |
|---|---|---|---|---|---|---|---|---|
| 2025/7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/11 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| 2025/12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 2026/2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |